294 related articles for article (PubMed ID: 38251375)
1. Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink.
Fernandez CJ; Alkhalifah M; Afsar H; Pappachan JM
Pathogens; 2024 Jan; 13(1):. PubMed ID: 38251375
[TBL] [Abstract][Full Text] [Related]
2. The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.
Huang CF; Liang PC; Tsai PC; Wei YJ; Huang CI; Wang CW; Jang TY; Yeh ML; Hsu PY; Hsieh MY; Lin YH; Dai CY; Chuang WL; Huang JF; Yu ML
J Gastroenterol Hepatol; 2024 Jan; 39(1):193-201. PubMed ID: 37731071
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
Yang DL; Liu SP; Wang HL; Li JR; Su JY; Li MJ; Teng YX; Deng ZJ; Li ZH; Huang JL; Guo PP; Ma L; Li ZZ; Zhong JH
Infect Agent Cancer; 2024 May; 19(1):21. PubMed ID: 38693556
[TBL] [Abstract][Full Text] [Related]
5. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.
Huang SC; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):320-331. PubMed ID: 36726053
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis.
Wang X; Xie Q
J Clin Transl Hepatol; 2022 Feb; 10(1):128-133. PubMed ID: 35233381
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
[No Abstract] [Full Text] [Related]
9. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
10. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
[TBL] [Abstract][Full Text] [Related]
11. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
12. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B.
Huang SC; Kao JH
J Formos Med Assoc; 2022 Nov; 121(11):2148-2151. PubMed ID: 35981929
[TBL] [Abstract][Full Text] [Related]
14. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.
Attia D; Abdel Alem S; El-Akel W; Abdel-Razek W; Eslam M; Fouad Y; Waked I
Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1581-1590. PubMed ID: 36168675
[TBL] [Abstract][Full Text] [Related]
16. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
17. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
[TBL] [Abstract][Full Text] [Related]
18. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
19. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.
Al-Omary A; Byth K; Weltman M; George J; Eslam M
J Dig Dis; 2022 Jan; 23(1):33-43. PubMed ID: 34902220
[TBL] [Abstract][Full Text] [Related]
20. Infections at the nexus of metabolic-associated fatty liver disease.
Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
